Molecular Diagnostics in Breast Cancer

2019 ◽  
pp. 89-102
Author(s):  
Rajeshwari Sinha ◽  
Sanghamitra Pati
Keyword(s):  
Breast Cancer ◽  
Molecular Diagnostics

Molecular diagnostics for determination of HER2 status in breast cancer

2003 ◽  
Vol 9 (1) ◽  
pp. 48-55 ◽  
Author(s):  
J.M.S. Bartlett ◽  
E. Mallon ◽  
T. Cooke
Keyword(s):  
Breast Cancer ◽  
Molecular Diagnostics ◽  
Her2 Status

scholarly journals Molecular Diagnostics for Identifying an Increased Likelihood of Recurrence of Breast Cancer

2009 ◽  
Vol 23 (S1) ◽  
Author(s):  
James L. Wittliff ◽  
Sarah A. Andres ◽  
D. Alan Kerr
Keyword(s):  
Breast Cancer ◽  
Molecular Diagnostics

scholarly journals Trends in incidence, molecular diagnostics, and treatment of patients with breast cancer in Kazakhstan, 2014-2019

2021 ◽  
Vol 62 (4) ◽  
pp. 16-23
Author(s):  
O. Shatkovskaya ◽  
D. Kaidarova ◽  
Z. Dushimova ◽  
M. Sagi ◽  
R. Abdrakhmanov
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Hormone Therapy ◽  
Molecular Diagnostics ◽  
Breast Cancer Incidence ◽  
Locally Advanced ◽  
Metastatic Breast ◽  
Breast Cancer Diagnosis ◽  
Advanced Breast ◽  
Ki 67

Relevance: Globocan reported 4,390 new breast cancer cases and 1,654 deaths from breast cancer in the Republic of Kazakhstan (RK) in 2020. Molecular diagnostics of breast cancer includes the determination of Hormone Receptor (HR), HER2, and Ki-67 status to detect patients with HR-positive tumors and administer effective treatment. Methods: This observational study included a retrospective analysis of incidence, molecular diagnostics, and treatment regimens in women with a confirmed breast cancer diagnosis aged 18 years old and older, registered in the RK Electronic Registry of Cancer Patients (ERCP) from 1 January 2014 till 31 December 2019. Results: In the study period (2014 to 2019), the number of breast cancer cases registered annually has doubled. The incidence increased by 46.9%. The share of locally advanced and advanced forms of breast cancer has decreased. The proportion of Luminal type A (HR+/HER2-) among newly diagnosed patients ranged from 17.9% to 30%. Chemotherapy and endocrine therapy with goserelin, buserelin, leuprorelin, and fulvestrant are standard first- and second-line treatments for HR+ breast cancer. Since fulvestrant indications have been expanded, more than 50% of patients with HR-positive advanced breast cancer receive fulvestrant as the first-line therapy. Conclusion: Breast cancer incidence growth and a decrease in the share of locally advanced and advanced breast cancer cases in the RK could be attributed to increased coverage of eligible women aged 40 to 70 with breast cancer mammographic screening. Although international guidelines support the administration of hormone therapy with or without targeted therapy in women with HR-positive, HER2-metastatic breast cancer, upfront use of chemotherapy remains common in the RK even in the absence of visceral crisis. The use of CDK4/6 inhibitor palbociclib in combination with hormone therapy has become routinely available since 2019.

scholarly journals Mass spectrometry-based serum proteome pattern analysis in molecular diagnostics of early stage breast cancer

2009 ◽  
Vol 7 (1) ◽  
pp. 60 ◽  
Author(s):  
Monika Pietrowska ◽  
Lukasz Marczak ◽  
Joanna Polanska ◽  
Katarzyna Behrendt ◽  
Elzbieta Nowicka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mass Spectrometry ◽  
Molecular Diagnostics ◽  
Pattern Analysis ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Serum Proteome

FEATURES

2018 ◽  
Vol 22 (06) ◽  
pp. 16-39
Keyword(s):  
Breast Cancer ◽  
Artificial Intelligence ◽  
Cancer Research ◽  
Immune System ◽  
Cancer Patients ◽  
Molecular Diagnostics ◽  
Multidisciplinary Team ◽  
Clinical Utility ◽  
Breast Cancer Patients ◽  
Exercise Regime

Artificial Intelligence: saving lives and securing the future. The best pill for cancer patients: An exercise regime. Across the divide: Multidisciplinary team to achieve better outcomes for breast cancer patients. The state of cancer research in Asia. Clinical utility of and access to cancer molecular diagnostics in Asia. Reprogramming the immune system against cancer.

scholarly journals The Emerging Role of the Molecular Diagnostics Laboratory in Breast Cancer Personalized Medicine

2013 ◽  
Vol 183 (4) ◽  
pp. 1075-1083 ◽  
Author(s):  
Francine B. De Abreu ◽  
Wendy A. Wells ◽  
Gregory J. Tsongalis
Keyword(s):  
Breast Cancer ◽  
Personalized Medicine ◽  
Molecular Diagnostics

scholarly journals Ribociclib for the treatment of hormone-positive HER2-negative breast cancer

2019 ◽  
pp. 72-80
Author(s):  
I. P. Ganshina ◽  
D. A. Filonenko ◽  
O. O. Gordeeva ◽  
E. V. Lubennikova ◽  
I. V. Kolyadina ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Molecular Diagnostics ◽  
Metastatic Breast ◽  
Topical Issue ◽  
High Efficacy ◽  
First Line ◽  
Mortality Pattern ◽  
First Line Therapy ◽  
Line Therapy

Breast cancer steadily holds leading market positions in the malignancy morbidity and mortality pattern. The treatment of metastatic breast cancer remains an extremely topical issue, when its aim is not only to prolong the patient’s life, but also to preserve its quality. Due to advances in molecular diagnostics, it has become possible to use several new classes of drugs in recent times. CDK4/6 inhibitors that demonstrate high efficacy in the first-line therapy for luminal metastatic breast cancer is one of these groups. This review presents data from recent registration studies and a description of observations from our own clinical experience.

Sign in / Sign up

Export Citation Format

Share Document